Immunoglobulin E (IgE) specific for Alnus serrulata pollen PR-10-like allergens (Aln s 1-specific IgE)

IgE antibodies specific for Alnus serrulata pollen PR-10–like allergens (primarily Aln s 1) are the central mediators of Type I hypersensitivity in individuals allergic to smooth alder pollen (WHO/IUIS Allergen Nomenclature). These antibodies are generated against PR-10 proteins, which are highly cross-reactive with the major birch allergen Bet v 1 (PubMed: 10851112). In sensitized individuals, these IgE molecules are bound to high-affinity FcεRI receptors on mast cells and basophils. Upon inhalation of alder pollen, the allergens cross-link the surface-bound IgE, triggering the release of inflammatory mediators like histamine and leukotrienes (StatPearls: Type I Hypersensitivity). This process leads to clinical manifestations such as allergic rhinitis, conjunctivitis, and potentially asthma. Therapeutic strategies include the use of omalizumab, which binds the Fc region of free IgE to prevent receptor binding (FDA Label: Xolair), and allergen-specific immunotherapy (AIT), which aims to induce immune tolerance and increase protective IgG4 levels (PubMed: 28041614). Monitoring of these specific IgE levels is crucial for diagnosis and for assessing the efficacy of immunotherapy.

Other names

Anti-Aln s 1 IgESmooth alder pollen-specific IgEIgE against Alnus serrulata PR-10 proteinsAln s 1 IgE

Omalizumab binds to the Cε3 domain of free IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils (FDA Label: Xolair). Allergen-specific immunotherapy (AIT) works by inducing T-cell tolerance and promoting the production of allergen-specific IgG4 antibodies that compete with IgE for allergen binding (PubMed: 28041614).